BD shares dip as outlook “unlikely to impress”
This article was originally published in Clinica
The share price of BD (Becton Dickinson) slipped by around 3% after the firm’s revenue outlook for next fiscal year failed to impress analysts. Shares fell to $68.51 on the NYSE at the close of markets yesterday, down from its opening price of $70.28.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals